Skip to content
Their Record

Senate Roll Call 185, 115th Congress · August 3, 2017

A bill to amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes.

Question before the chamber: On the Cloture Motion

96 yea · 1 nayCloture Motion Agreed to3 not voting or present
Democrat45 yea · 0 nay
Republican49 yea · 0 nay
Independent2 yea · 1 nay

Solid = yea, faded = nay.

The measure

H.R. 2430

FDA Reauthorization Act of 2017

Policy area: Health — assigned by Library of Congress subject specialists, not by this site.

How this vote is scored

Which tracked issues this roll call counts toward, and which way a yea vote moves a member on each. Direction is decided per issue, because one bill can push two issues opposite ways.

  • Health CareDirection unreadable — not scored

    excluded:model-unclear (0.90) FDA user fee reauthorizations regulate drug review procedures rather than insurance coverage.

    Tagged by: policy-area:Health

    Axis: Expand coverage ← → Restrict coverage

Who voted which way

Every member recorded on this roll call, with the party they sat with at the time.

Vote records come from Voteview (voteview.com); bill titles and policy areas from the congress.gov API. See methodology for how the record was built.